Cargando…
Nanocarriers for anticancer drugs: Challenges and perspectives
Cancer is the second most common cause of death globally, surpassed only by cardiovascular disease. One of the hallmarks of cancer is uncontrolled cell division and resistance to cell death. Multiple approaches have been developed to tackle this disease, including surgery, radiotherapy and chemother...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130109/ https://www.ncbi.nlm.nih.gov/pubmed/35645591 http://dx.doi.org/10.1016/j.sjbs.2022.103298 |
_version_ | 1784712917007990784 |
---|---|
author | Alqosaibi, Amany I. |
author_facet | Alqosaibi, Amany I. |
author_sort | Alqosaibi, Amany I. |
collection | PubMed |
description | Cancer is the second most common cause of death globally, surpassed only by cardiovascular disease. One of the hallmarks of cancer is uncontrolled cell division and resistance to cell death. Multiple approaches have been developed to tackle this disease, including surgery, radiotherapy and chemotherapy. Although chemotherapy is used primarily to control cell division and induce cell death, some cancer cells are able to resist apoptosis and develop tolerance to these drugs. The side effects of chemotherapy are often overwhelming, and patients can experience more adverse effects than benefits. Furthermore, the bioavailability and stability of drugs used for chemotherapy are crucial issues that must be addressed, and there is therefore a high demand for a reliable delivery system that ensures fast and accurate targeting of treatment. In this review, we discuss the different types of nanocarriers, their properties and recent advances in formulations, with respect to relevant advantages and disadvantages of each. |
format | Online Article Text |
id | pubmed-9130109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91301092022-05-26 Nanocarriers for anticancer drugs: Challenges and perspectives Alqosaibi, Amany I. Saudi J Biol Sci Review Cancer is the second most common cause of death globally, surpassed only by cardiovascular disease. One of the hallmarks of cancer is uncontrolled cell division and resistance to cell death. Multiple approaches have been developed to tackle this disease, including surgery, radiotherapy and chemotherapy. Although chemotherapy is used primarily to control cell division and induce cell death, some cancer cells are able to resist apoptosis and develop tolerance to these drugs. The side effects of chemotherapy are often overwhelming, and patients can experience more adverse effects than benefits. Furthermore, the bioavailability and stability of drugs used for chemotherapy are crucial issues that must be addressed, and there is therefore a high demand for a reliable delivery system that ensures fast and accurate targeting of treatment. In this review, we discuss the different types of nanocarriers, their properties and recent advances in formulations, with respect to relevant advantages and disadvantages of each. Elsevier 2022-06 2022-04-22 /pmc/articles/PMC9130109/ /pubmed/35645591 http://dx.doi.org/10.1016/j.sjbs.2022.103298 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Alqosaibi, Amany I. Nanocarriers for anticancer drugs: Challenges and perspectives |
title | Nanocarriers for anticancer drugs: Challenges and perspectives |
title_full | Nanocarriers for anticancer drugs: Challenges and perspectives |
title_fullStr | Nanocarriers for anticancer drugs: Challenges and perspectives |
title_full_unstemmed | Nanocarriers for anticancer drugs: Challenges and perspectives |
title_short | Nanocarriers for anticancer drugs: Challenges and perspectives |
title_sort | nanocarriers for anticancer drugs: challenges and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130109/ https://www.ncbi.nlm.nih.gov/pubmed/35645591 http://dx.doi.org/10.1016/j.sjbs.2022.103298 |
work_keys_str_mv | AT alqosaibiamanyi nanocarriersforanticancerdrugschallengesandperspectives |